Events and Presentations
IGC PHARMA Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitation
Both the primary and secondary objectives aim to evaluate the efficacy of IGC-AD1 in reducing agitation as assessed by the CMAI at week 2 and week 6 respectively.
Psychosis in Parkinson
Parkinson’s awareness month
____________________________
Parkinson’s disease psychosis is a neuropsychiatric complication that affects more than 20% of patients affected by Parkinson’s. Common symptoms involve visual or auditory hallucinations, distorted perception, and experiences. More challenging symptoms may occur in the form of delusions, which
often cause agitation, aggressiveness, and affect the quality of life of the patient and their families.
IGC Pharma Releases Positive Interim Analysis Of Its Ongoing Phase 2 Trial In Alzheimer’s Research
By: Faith Ashmore Benzinga Staff Writer As of 2023, the estimated number of Americans living with Alzheimer’s disease was 6.7 million. However, a lesser-known subsection of Alzheimer’s
IGC Pharma Advances in Alzheimer’s Research from Pre-clinical Studies to Phase Two Trials with its Novel Therapy Candidate IGC-AD1
By: Faith Ashmore Benzinga Staff Writer Alzheimer’s disease, a progressive neurological disorder, affects around 24 million individuals worldwide. It is characterized by memory loss, cognitive decline
The Synesthetic Brain
Synesthesia is a complex experience that involves perceiving the elements of the world with more than one sense. By integrating the knowledge of neuroscience with these aspects of perception, scientists have been able to map synchronous patterns of activation in brain regions that do not entirely relate to the stimulus nature. The intriguing nature of this process invites people to be more aware of what they can perceive in a world saturated with external information.
Artificial Intelligence and Alzheimer’s Disease
In Alzheimer’s disease research, the integration of artificial intelligence (AI) enables researchers to uncover patterns and biomarkers faster, facilitating earlier diagnosis and personalized therapies. Embracing these new technologies not only enhances the understanding of AD but also propels the development of innovative treatments for this complex neurological condition.